Evidence map›Paper›PMID 38474332›Full record

ArticleCells2024

The CDK Inhibitor Dinaciclib Improves Cisplatin Response in Nonseminomatous Testicular Cancer: A Preclinical Study.

Elisa Rossini, Mariangela Tamburello, Andrea Abate, Silvia Zini, Giovanni Ribaudo, Alessandra Gianoncelli, Stefano Calza, Francesca Valcamonico, Nazareno R Suardi, Giuseppe Mirabella and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
4.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Serine protease HtrA promotesScience advances · 2026
    Article
  4. Article
  5. Review
  6. Review
  7. Zebrafish as a model system for studying reproductive diseases.Frontiers in cell and developmental biology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Elisa RossiniSection of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy.ORCID 0000-0002-4936-8880
Mariangela TamburelloSection of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy.ORCID 0000-0001-7827-0025
Andrea AbateSection of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy.
Silvia ZiniSection of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy.ORCID 0000-0001-9609-5398
Giovanni RibaudoSection of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy.ORCID 0000-0003-3679-5530
Alessandra GianoncelliSection of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy.ORCID 0000-0002-0816-5163
Stefano CalzaUnit of Biostatistics and Bioinformatics, Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy.ORCID 0000-0003-4996-7995
Francesca ValcamonicoOncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia at ASST Spedali Civili di Brescia, 25123 Brescia, Italy.
Nazareno R SuardiUrology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia at ASST Spedali Civili di Brescia, 25123 Brescia, Italy.
Giuseppe MirabellaUrology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia at ASST Spedali Civili di Brescia, 25123 Brescia, Italy.
Alfredo BerrutiOncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia at ASST Spedali Civili di Brescia, 25123 Brescia, Italy.ORCID 0000-0002-2952-9560
Sandra SigalaSection of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy.ORCID 0000-0003-3294-4121
University of Brescia · ITAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMost patients with testicular germ cell tumors (GCTs) are treated with cisplatin (CP)-based chemotherapy. However, some of them may develop CP resistance and therefore represent a clinical challenge. Cyclin-dependent kinase 5 (CDK5) is involved in chemotherapy resistance in different types of cancer. Here, we investigated the possible role of CDK5 and other CDKs targeted by dinaciclib in nonseminoma cell models (both CP-sensitive and CP-resistant), evaluating the potential of the CDK inhibitor dinaciclib as a single/combined agent for the treatment of advanced/metastatic testicular cancer (TC).

methodsThe effects of dinaciclib and CP on sensitive and resistant NT2/D1 and NCCIT cell viability and proliferation were evaluated using MTT assays and direct count methods. Flow cytometry cell-cycle analysis was performed. The protein expression was assessed via Western blotting. The in vivo experiments were conducted in zebrafish embryos xenografted with TC cells.

resultsAmong all the CDKs analyzed, CDK5 protein expression was significantly higher in CP-resistant models. Dinaciclib reduced the cell viability and proliferation in each cell model, inducing changes in cell-cycle distribution. In drug combination experiments, dinaciclib enhances the CP effect both in vitro and in the zebrafish model.

conclusionsDinaciclib, when combined with CP, could be useful for improving nonseminoma TC response to CP.

Indexed as

CisplatinCyclic N-OxidesIndolizinesNeoplasms, Germ Cell and EmbryonalPyridinium CompoundsTesticular NeoplasmsAnimalsCell ProliferationHumansMaleProtein Kinase InhibitorsZebrafishCisplatinCyclic N-OxidesdinaciclibIndolizinesProtein Kinase InhibitorsPyridinium CompoundsCDK inhibitorscisplatin resistancecombined treatmentdinaciclibtesticular cancerzebrafish xenograft

Identifiers

PMID38474332
PMCPMC10931172
OpenAlexW4391969897

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.